teva-ticagrelor tablet
teva canada limited - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors
teva-ticagrelor tablet
teva canada limited - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors
apo-ticagrelor tablet
apotex inc - ticagrelor - tablet - 60mg - ticagrelor 60mg - platelet aggregation inhibitors
apo-ticagrelor tablet
apotex inc - ticagrelor - tablet - 90mg - ticagrelor 90mg - platelet aggregation inhibitors
ag-ticagrelor tablet
angita pharma inc. - ticagrelor - tablet - 60mg - ticagrelor 60mg
ag-ticagrelor tablet
angita pharma inc. - ticagrelor - tablet - 90mg - ticagrelor 90mg
ticagrelor sandoz
sandoz new zealand limited - ticagrelor 60mg - film coated tablet - 60 mg - active: ticagrelor 60mg excipient: calcium hydrogen phosphate dihydrate maize starch mannitol opadry pink 88a240025 purified talc purified water sodium stearyl fumarate starch - co-administered with acetylsalicylic acid (aspirin), this product is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) " in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). " in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.
ticagrelor sandoz
sandoz new zealand limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate maize starch mannitol opadry yellow 88a220017 purified talc purified water sodium stearyl fumarate starch - co-administered with acetylsalicylic acid (aspirin), this product is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) " in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). " in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.
m-ticagrelor tablet
mantra pharma inc - ticagrelor - tablet - 60mg - ticagrelor 60mg
m-ticagrelor tablet
mantra pharma inc - ticagrelor - tablet - 90mg - ticagrelor 90mg